Bridge Therapeutics, a late development-stage specialty pharmaceutical company, has added Steven Passik PhD to its Scientific Advisory Board, it was reported yesterday.
Dr Passik PhD, Clinical Psychology, is a leader and researcher in pain management and addiction. He has written extensively on the treatment of cancer and AIDS patient's pain management. He has been a principal investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organisations. He has been the recipient of numerous awards for his excellence in clinical research.
Dr Greg Sullivan, chief science officer and founder of Bridge Therapeutics said, 'Dr Passik has a wealth of knowledge on the practical application of pain management in the real world, not just in the clinical setting. I'm excited to see what he will add to Bridge's efforts in developing safer chronic pain treatments.'
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients